Student or educator? Sign up with your school email and get 6 months of Pro free.
Cited by 184

The DOI matches its Crossref record; 63 of the 63 references it cites were found in a registry or an index.

Rational designs of in vivo CRISPR-Cas delivery systems

Xu, Cong-Fei, Chen, Guo-Jun, Luo, Ying-Li, Zhang, Yue, Zhao, Gui, Lu, Zi-Dong, Czarna, Anna, Gu, Zhen, Wang, Jun·2021·Advanced Drug Delivery Reviews

Abstract

The CRISPR-Cas system initiated a revolution in genome editing when it was, for the first time, demonstrated success in the mammalian cells. Today, scientists are able to readily edit the genome, regulate gene transcription, engineer posttranscriptional events, and image nucleic acids using CRISPR-Cas-based tools. However, to efficiently transport CRISPR-Cas into target tissues/cells remains challenging due to many extra- and intra-cellular barriers, therefore largely limiting the applications of CRISPR-based therapeutics in vivo. In this review, we summarize the features of plasmid-, RNA- and ribonucleoprotein (RNP)-based CRISPR-Cas therapeutics. Then, we survey the current in vivo delivery systems. Finally, we specify the requirements for efficient in vivo delivery in clinical settings, and highlight both efficiency and safety for different CRISPR-Cas tools.

Overview

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1016/j.addr.2019.11.005

Cites

63 of 63 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Research works printed but not linked: 140

  1. Cong, 2013, Multiplex genome engineering using CRISPR/Cas systems, Science, 339, 819, 10.1126/science.1231143 · DOI · Paper page
  2. Adli, 2018, The CRISPR tool kit for genome editing and beyond, Nat. Commun., 9, 1911, 10.1038/s41467-018-04252-2 · DOI · Paper page
  3. Hsu, 2014, Development and applications of CRISPR-Cas9 for genome engineering, Cell, 157, 1262, 10.1016/j.cell.2014.05.010 · DOI · Paper page
  4. Nelson, 2019, Long-term evaluation of AAV-CRISPR genome editing for duchenne muscular dystrophy, Nat. Med., 25, 427, 10.1038/s41591-019-0344-3 · DOI · Paper page
  5. Wu, 2019, Highly efficient therapeutic gene editing of human hematopoietic stem cells, Nat. Med., 25, 776, 10.1038/s41591-019-0401-y · DOI · Paper page
  6. Pavel-Dinu, 2019, Gene correction for SCID-X1 in long-term hematopoietic stem cells, Nat. Commun., 10, 2021, 10.1038/s41467-019-10080-9 · DOI
  7. de Buhr, 2018, Harnessing CRISPR to combat human viral infections, Curr. Opin. Immunol., 54, 123, 10.1016/j.coi.2018.06.002 · DOI
  8. Ewart, 2019, Gene editing for inflammatory disorders, Ann. Rheum. Dis., 78, 6, 10.1136/annrheumdis-2018-213454 · DOI
  9. Yin, 2019, CRISPR-Cas: a tool for cancer research and therapeutics, Nat. Rev. Clin. Oncol., 16, 281, 10.1038/s41571-019-0166-8 · DOI · Paper page
  10. Gao, 2019, Therapeutic potential of CRISPR/Cas9 gene editing in engineered T-cell therapy, Cancer Med., 8, 4254, 10.1002/cam4.2257 · DOI
  11. Tan, 2019, Engineering of high-precision base editors for site-specific single nucleotide replacement, Nat. Commun., 10, 439, 10.1038/s41467-018-08034-8 · DOI · Paper page
  12. Wu, 2019, Progress and challenges for live-cell imaging of genomic loci using CRISPR-based platforms, Genomics, Proteomics Bioinf., 17, 119
  13. Wilbie, 2019, Delivery aspects of CRISPR/Cas for in vivo genome editing, Acc. Chem. Res., 52, 1555, 10.1021/acs.accounts.9b00106 · DOI · Paper page
  14. Wan, 2019, Material solutions for delivery of CRISPR/Cas-based genome editing tools: current status and future outlook, Mater. Today, 26, 40, 10.1016/j.mattod.2018.12.003 · DOI
  15. Eoh, 2019, Biomaterials as vectors for the delivery of CRISPR-Cas9, Biomater. Sci., 7, 1240, 10.1039/C8BM01310A · DOI
  16. Givens, 2018, Nanoparticle-based delivery of CRISPR/Cas9 genome-editing therapeutics, AAPS J., 20, 108, 10.1208/s12248-018-0267-9 · DOI
  17. Piotrowski-Daspit, 2018, Debugging the genetic code: non-viral in vivo delivery of therapeutic genome editing technologies, Curr. Opin. Biomed. Eng., 7, 24, 10.1016/j.cobme.2018.08.002 · DOI
  18. Mout, 2017, In vivo delivery of CRISPR/Cas9 for therapeutic gene editing: progress and challenges, Bioconjug. Chem., 28, 880, 10.1021/acs.bioconjchem.7b00057 · DOI · Paper page
  19. Wang, 2019, Delivery of CRISPR/Cas9 by novel strategies for gene therapy, Chembiochem, 20, 634, 10.1002/cbic.201800629 · DOI
  20. LaFountaine, 2015, Delivery and therapeutic applications of gene editing technologies ZFNs, TALENs, and CRISPR/Cas9, Int. J. Pharm., 494, 180, 10.1016/j.ijpharm.2015.08.029 · DOI · Paper page
  21. Ishino, 1987, Nucleotide sequence of the iap gene, responsible for alkaline phosphatase isozyme conversion in Escherichia coli, and identification of the gene product, J. Bacteriol., 169, 5429, 10.1128/jb.169.12.5429-5433.1987 · DOI · Paper page
  22. Mojica, 2000, Biological significance of a family of regularly spaced repeats in the genomes of archaea, bacteria and mitochondria, Mol. Microbiol., 36, 244, 10.1046/j.1365-2958.2000.01838.x · DOI · Paper page
  23. Mojica, 2005, Intervening sequences of regularly spaced prokaryotic repeats derive from foreign genetic elements, J. Mol. Evol., 60, 174, 10.1007/s00239-004-0046-3 · DOI · Paper page
  24. Pourcel, 2005, CRISPR elements in Yersinia pestis acquire new repeats by preferential uptake of bacteriophage DNA, and provide additional tools for evolutionary studies, Microbiology, 151, 653, 10.1099/mic.0.27437-0 · DOI · Paper page
  25. Bolotin, 2005, Clustered regularly interspaced short palindrome repeats (CRISPRs) have spacers of extrachromosomal origin, Microbiology, 151, 2551, 10.1099/mic.0.28048-0 · DOI · Paper page
  26. Makarova, 2002, A DNA repair system specific for thermophilic archaea and bacteria predicted by genomic context analysis, Nucleic Acids Res., 30, 482, 10.1093/nar/30.2.482 · DOI · Paper page
  27. Jansen, 2002, Identification of genes that are associated with DNA repeats in prokaryotes, Mol. Microbiol., 43, 1565, 10.1046/j.1365-2958.2002.02839.x · DOI · Paper page
  28. Barrangou, 2007, CRISPR provides acquired resistance against viruses in prokaryotes, Science, 315, 1709, 10.1126/science.1138140 · DOI · Paper page
  29. Brouns, 2008, Small CRISPR RNAs guide antiviral defense in prokaryotes, Science, 321, 960, 10.1126/science.1159689 · DOI · Paper page
  30. Marraffini, 2008, CRISPR interference limits horizontal gene transfer in staphylococci by targeting DNA, Science, 322, 1843, 10.1126/science.1165771 · DOI · Paper page
  31. Garneau, 2010, The CRISPR/Cas bacterial immune system cleaves bacteriophage and plasmid DNA, Nature, 468, 67, 10.1038/nature09523 · DOI · Paper page
  32. Jinek, 2012, A programmable dual-RNA-guided DNA endonuclease in adaptive bacterial immunity, Science, 337, 816, 10.1126/science.1225829 · DOI · Paper page
  33. Qi, 2013, Repurposing CRISPR as an RNA-guided platform for sequence-specific control of gene expression, Cell, 152, 1173, 10.1016/j.cell.2013.02.022 · DOI · Paper page
  34. Maeder, 2013, CRISPR RNA-guided activation of endogenous human genes, Nat. Methods, 10, 977, 10.1038/nmeth.2598 · DOI · Paper page
  35. Perez-Pinera, 2013, RNA-guided gene activation by CRISPR-Cas9-based transcription factors, Nat. Methods, 10, 973, 10.1038/nmeth.2600 · DOI · Paper page
  36. Chavez, 2015, Highly efficient Cas9-mediated transcriptional programming, Nat. Methods, 12, 326, 10.1038/nmeth.3312 · DOI · Paper page
  37. Tanenbaum, 2014, A protein-tagging system for signal amplification in gene expression and fluorescence imaging, Cell, 159, 635, 10.1016/j.cell.2014.09.039 · DOI · Paper page
  38. Kuscu, 2016, CRISPR-Cas9-AID base editor is a powerful gain-of-function screening tool, Nat. Methods, 13, 983, 10.1038/nmeth.4076 · DOI
  39. Morita, 2016, Targeted DNA demethylation in vivo using dCas9-peptide repeat and scFv-TET1 catalytic domain fusions, Nat. Biotechnol., 34, 1060, 10.1038/nbt.3658 · DOI · Paper page
  40. Kearns, 2015, Functional annotation of native enhancers with a Cas9-histone demethylase fusion, Nat. Methods, 12, 401, 10.1038/nmeth.3325 · DOI · Paper page
  41. Liang, 2011, Engineering the ABA plant stress pathway for regulation of induced proximity, Sci. Signal., 4, 10.1126/scisignal.2001449 · DOI · Paper page
  42. Qin, 2017, Live cell imaging of low- and non-repetitive chromosome loci using CRISPR-Cas9, Nat. Commun., 8, 14725, 10.1038/ncomms14725 · DOI · Paper page
  43. Tsoi, 2010, Characterization of condensed plasmid DNA models for studying the direct effect of ionizing radiation, Biophys. Chem., 147, 104, 10.1016/j.bpc.2009.12.006 · DOI
  44. Fritz, 2002, Electronic detection of DNA by its intrinsic molecular charge, Proc. Natl. Acad. Sci. U. S. A., 99, 14142, 10.1073/pnas.232276699 · DOI · Paper page
  45. Luo, 2018, Macrophage-specific in vivo gene editing using cationic lipid-assisted polymeric nanoparticles, ACS Nano, 12, 994, 10.1021/acsnano.7b07874 · DOI · Paper page
  46. Smoyer, 2014, Breaking down the wall: the nuclear envelope during mitosis, Curr. Opin. Cell Biol., 26, 1, 10.1016/j.ceb.2013.08.002 · DOI
  47. Branden, 1999, A peptide nucleic acid-nuclear localization signal fusion that mediates nuclear transport of DNA, Nat. Biotechnol., 17, 784, 10.1038/11726 · DOI · Paper page
  48. Copolovici, 2014, Cell-penetrating peptides: design, synthesis, and applications, ACS Nano, 8, 1972, 10.1021/nn4057269 · DOI · Paper page
  49. Wu, 2016, Translation dynamics of single mRNAs in live cells and neurons, Science, 352, 1430, 10.1126/science.aaf1084 · DOI · Paper page
  50. Bak, 2015, Chemically modified guide RNAs enhance CRISPR/Cas genome editing in human primary cells, Hum. Gene Ther., 26, A11
  51. DeWitt, 2017, Genome editing via delivery of Cas9 ribonucleoprotein, Methods, 121-122, 9, 10.1016/j.ymeth.2017.04.003 · DOI · Paper page
  52. Gagnon, 2014, Efficient mutagenesis by Cas9 protein-mediated oligonucleotide insertion and large-scale assessment of single-guide RNAs, PLoS One, 9, 10.1371/journal.pone.0098186 · DOI · Paper page
  53. Wright, 2015, Rational design of a split-Cas9 enzyme complex, Proc. Natl. Acad. Sci. U. S. A., 112, 2984, 10.1073/pnas.1501698112 · DOI · Paper page
  54. Hansen-Bruhn, 2018, Active intracellular delivery of a Cas9/sgRNA complex using ultrasound-propelled nanomotors, Angew. Chem. Int. Ed., 57, 2657, 10.1002/anie.201713082 · DOI · Paper page
  55. Crudele, 2018, Cas9 immunity creates challenges for CRISPR gene editing therapies, Nat. Commun., 9, 3497, 10.1038/s41467-018-05843-9 · DOI · Paper page
  56. Song, 2016, RS-1 enhances CRISPR/Cas9- and TALEN-mediated knock-in efficiency, Nat. Commun., 7, 10548, 10.1038/ncomms10548 · DOI · Paper page
  57. Cao, 2019, Nontoxic nanopore electroporation for effective intracellular delivery of biological macromolecules, Proc. Natl. Acad. Sci. U. S. A., 116, 7899, 10.1073/pnas.1818553116 · DOI
  58. Wu, 2017, Efficient in vivo gene editing using ribonucleoproteins in skin stem cells of recessive dystrophic epidermolysis bullosa mouse model, Proc. Natl. Acad. Sci. U. S. A., 114, 1660, 10.1073/pnas.1614775114 · DOI
  59. Maresch, 2016, Multiplexed pancreatic genome engineering and cancer induction by transfection-based CRISPR/Cas9 delivery in mice, Nat. Commun., 7, 10770, 10.1038/ncomms10770 · DOI · Paper page
  60. Han, 2015, CRISPR-Cas9 delivery to hard-to-transfect cells via membrane deformation, Sci. Adv., 1, 10.1126/sciadv.1500454 · DOI · Paper page
  61. Wirth, 2013, History of gene therapy, Gene, 525, 162, 10.1016/j.gene.2013.03.137 · DOI · Paper page
  62. Samulski, 2014, AAV-mediated gene therapy for research and therapeutic purposes, Annu. Rev. Virol., 1, 427, 10.1146/annurev-virology-031413-085355 · DOI · Paper page
  63. Xu, 2019, Development of "CLAN" nanomedicine for nucleic acid therapeutics, Small, 15, 10.1002/smll.201900055 · DOI
  64. Yang, 2011, Systemic delivery of siRNA with cationic lipid assisted PEG-PLA nanoparticles for cancer therapy, J. Control. Release, 156, 203, 10.1016/j.jconrel.2011.07.035 · DOI · Paper page
  65. Xu, 2016, Tumor acidity-sensitive linkage-bridged block copolymer for therapeutic siRNA delivery, Biomaterials, 88, 48, 10.1016/j.biomaterials.2016.02.031 · DOI
  66. Liu, 2018, Systemic delivery of CRISPR/Cas9 with PEG-PLGA nanoparticles for chronic myeloid leukemia targeted therapy, Biomater. Sci., 6, 1592, 10.1039/C8BM00263K · DOI
  67. Burke, 2010, BCR-ABL: a multi-faceted promoter of DNA mutation in chronic myelogeneous leukemia, Leukemia, 24, 1105, 10.1038/leu.2010.67 · DOI
  68. Liu, 2018, Optimization of lipid-assisted nanoparticle for disturbing neutrophils-related inflammation, Biomaterials, 172, 92, 10.1016/j.biomaterials.2018.04.052 · DOI
  69. Li, 2018, Optimized nanoparticle-mediated delivery of CRISPR-Cas9 system for B cell intervention, Nano Res., 11, 6270, 10.1007/s12274-018-2150-5 · DOI
  70. Holness, 1993, Molecular cloning of CD68, a human macrophage marker related to lysosomal glycoproteins, Blood, 81, 1607, 10.1182/blood.V81.6.1607.1607 · DOI · Paper page
  71. Schuh, 2018, Gene editing of MPS I human fibroblasts by co-delivery of a CRISPR/Cas9 plasmid and a donor oligonucleotide using nanoemulsions as nonviral carriers, Eur. J. Pharm. Biopharm., 122, 158, 10.1016/j.ejpb.2017.10.017 · doi:10.1016/j.ejpb.2017.10.017
  72. He, 2018, In vivo ovarian cancer gene therapy using CRISPR-Cas9, Hum. Gene Ther., 29, 223, 10.1089/hum.2017.209 · DOI
  73. Li, 2019, Knockdown of hypoxia-inducible factor-1 alpha by tumor targeted delivery of CRISPR/Cas9 system suppressed the metastasis of pancreatic cancer, J. Control. Release, 304, 204, 10.1016/j.jconrel.2019.05.019 · DOI
  74. Dharmalingam, 2017, Green transfection: cationic lipid nanocarrier system derivatized from vegetable fat, palmstearin enhances nucleic acid transfections, ACS Omega, 2, 7892, 10.1021/acsomega.7b00935 · DOI
  75. Zhang, 2019, Cationic polymer-mediated CRISPR/Cas9 plasmid delivery for genome editing, Macromol. Rapid Commun., 40, 10.1002/marc.201800068 · DOI
  76. Ryu, 2018, Effective PEI-mediated delivery of CRISPR-Cas9 complex for targeted gene therapy, Nanomedicine, 14, 2095, 10.1016/j.nano.2018.06.009 · DOI
  77. Yan, 2015, Modulation of gene expression by polymer nanocapsule delivery of DNA cassettes encoding small RNAs, PLoS One, 10
  78. Liang, 2017, Tumor cell-targeted delivery of CRISPR/Cas9 by aptamer-functionalized lipopolymer for therapeutic genome editing of VEGFA in osteosarcoma, Biomaterials, 147, 68, 10.1016/j.biomaterials.2017.09.015 · DOI · Paper page
  79. Liu, 2019, Multistage delivery nanoparticle facilitates efficient CRISPR/dCas9 activation and tumor growth suppression in vivo, Adv. Sci., 6, 1801423, 10.1002/advs.201801423 · DOI · Paper page
  80. Wang, 2014, A fluorinated dendrimer achieves excellent gene transfection efficacy at extremely low nitrogen to phosphorus ratios, Nat. Commun., 5, 3053, 10.1038/ncomms4053 · DOI · Paper page
  81. Qi, 2018, Fluorinated acid-labile branched hydroxyl-rich nanosystems for flexible and robust delivery of plasmids, Small, 14, 10.1002/smll.201803061 · DOI
  82. Lehto, 2016, Peptides for nucleic acid delivery, Adv. Drug Deliv. Rev., 106, 172, 10.1016/j.addr.2016.06.008 · DOI · Paper page
  83. Wang, 2018, Thermo-triggered release of CRISPR-Cas9 system by lipid-encapsulated gold nanoparticles for tumor therapy, Angew. Chem. Int. Ed., 57, 1491, 10.1002/anie.201708689 · DOI · Paper page
  84. Timin, 2018, Efficient gene editing via non-viral delivery of CRISPR-Cas9 system using polymeric and hybrid microcarriers, Nanomedicine, 14, 97, 10.1016/j.nano.2017.09.001 · DOI
  85. Lu, 2011, Ionic polypeptides with unusual helical stability, Nat. Commun., 2, 206, 10.1038/ncomms1209 · DOI · Paper page
  86. Lao, 2018, HPV oncogene manipulation using nonvirally delivered CRISPR/Cas9 or natronobacterium gregoryi argonaute, Adv. Sci., 5, 1700540, 10.1002/advs.201700540 · DOI
  87. Zhang, 2019, CRISPR/Cas9 delivery mediated with hydroxyl-rich nanosystems for gene editing in aorta, Adv. Sci., 6, 1900386, 10.1002/advs.201900386 · DOI
  88. Liu, 2018, Tumor targeted genome editing mediated by a multi-functional gene vector for regulating cell behaviors, J. Control. Release, 291, 90, 10.1016/j.jconrel.2018.10.018 · DOI
  89. Zhu, 2018, Nanoparticles based on poly (beta-amino ester) and HPV16-targeting CRISPR/shRNA as potential drugs for HPV16-related cervical malignancy, Mol. Ther., 26, 2443, 10.1016/j.ymthe.2018.07.019 · DOI
  90. Lin, 2018, Exosome-liposome hybrid nanoparticles deliver CRISPR/Cas9 system in MSCs, Adv. Sci., 5, 1700611, 10.1002/advs.201700611 · DOI · Paper page
  91. Killian, 2019, Antibody-targeted chromatin enables effective intracellular delivery and functionality of CRISPR/Cas9 expression plasmids, Nucleic Acids Res., 47, 10.1093/nar/gkz137 · DOI
  92. Guo, 2019, Therapeutic genome editing of triple-negative breast tumors using a noncationic and deformable nanolipogel, Proc. Natl. Acad. Sci. U. S. A., 116, 18295, 10.1073/pnas.1904697116 · DOI
  93. Li, 2019, A rationally designed semiconducting polymer brush for NIR-II imaging-guided light-triggered remote control of CRISPR/Cas9 genome editing, Adv. Mater., 31
  94. Zhang, 2019, Genome editing with mRNA encoding ZFN, TALEN, and Cas9, Mol. Ther., 27, 735, 10.1016/j.ymthe.2019.01.014 · DOI · Paper page
  95. Xu, 2018, Targeting of NLRP3 inflammasome with gene editing for the amelioration of inflammatory diseases, Nat. Commun., 9, 4092, 10.1038/s41467-018-06522-5 · DOI · Paper page
  96. Zhang, 2019, In situ repurposing of dendritic cells with CRISPR/Cas9-based nanomedicine to induce transplant tolerance, Biomaterials, 217, 119302, 10.1016/j.biomaterials.2019.119302 · DOI
  97. Liu, 2016, Recent progress of microfluidics in translational applications, Adv. Healthcare Mater., 5, 871, 10.1002/adhm.201600009 · DOI
  98. Maeki, 2018, Advances in microfluidics for lipid nanoparticles and extracellular vesicles and applications in drug delivery systems, Adv. Drug Deliv. Rev., 128, 84, 10.1016/j.addr.2018.03.008 · DOI · Paper page
  99. Li, 2015, An orthogonal array optimization of lipid-like nanoparticles for mRNA delivery in vivo, Nano Lett., 15, 8099, 10.1021/acs.nanolett.5b03528 · DOI · Paper page
  100. Usman, 2018, Efficient RNA drug delivery using red blood cell extracellular vesicles, Nat. Commun., 9, 2359, 10.1038/s41467-018-04791-8 · DOI · Paper page
  101. Sun, 2014, Cocoon-like self-degradable DNA nanoclew for anticancer drug delivery, J. Am. Chem. Soc., 136, 14722, 10.1021/ja5088024 · DOI · Paper page
  102. Gasiunas, 2012, Cas9-crRNA ribonucleoprotein complex mediates specific DNA cleavage for adaptive immunity in bacteria, Proc. Natl. Acad. Sci. U. S. A., 109, E2579, 10.1073/pnas.1208507109 · DOI · Paper page
  103. Chen, 2019, A biodegradable nanocapsule delivers a Cas9 ribonucleoprotein complex for in vivo genome editing, Nat. Nanotechnol., 14, 974, 10.1038/s41565-019-0539-2 · DOI · Paper page
  104. Shahbazi, 2019, Targeted homology-directed repair in blood stem and progenitor cells with CRISPR nanoformulations, Nat. Mater., 18, 1124, 10.1038/s41563-019-0385-5 · DOI · Paper page
  105. Ray, 2018, CRISPRed macrophages for cell-based cancer immunotherapy, Bioconjug. Chem., 29, 445, 10.1021/acs.bioconjchem.7b00768 · DOI
  106. Wang, 2016, Efficient delivery of genome-editing proteins using bioreducible lipid nanoparticles, Proc. Natl. Acad. Sci. U. S. A., 113, 2868, 10.1073/pnas.1520244113 · DOI · Paper page
  107. Li, 2019, Intracellular delivery and biodistribution study of CRISPR/Cas9 ribonucleoprotein loaded bioreducible lipidoid nanoparticles, Biomater. Sci., 7, 596, 10.1039/C8BM00637G · DOI
  108. Kang, 2018, Nonviral genome editing based on a polymer-derivatized CRISPR nanocomplex for targeting bacterial pathogens and antibiotic resistance, Bioconjug. Chem., 29, 3936, 10.1021/acs.bioconjchem.8b00771 · DOI
  109. Cho, 2019, Lecithin nano-liposomal particle as a CRISPR/Cas9 complex delivery system for treating type 2 diabetes, J. Nanobiotechnol., 17, 19, 10.1186/s12951-019-0452-8 · DOI
  110. Kim, 2018, Simple in vivo gene editing via direct self-assembly of Cas9 ribonucleoprotein complexes for cancer treatment, ACS Nano, 12, 7750, 10.1021/acsnano.8b01670 · DOI
  111. Qazi, 2016, Programmed self-assembly of an active P22-Cas9 nanocarrier system, Mol. Pharm., 13, 1191, 10.1021/acs.molpharmaceut.5b00822 · DOI
  112. Rouet, 2019, Efficient intracellular delivery of CRISPR-Cas ribonucleoproteins through receptor mediated endocytosis, ACS Chem. Biol., 14, 554, 10.1021/acschembio.9b00116 · DOI
  113. Park, 2019, In vivo neuronal gene editing via CRISPR-Cas9 amphiphilic nanocomplexes alleviates deficits in mouse models of Alzheimer's disease, Nat. Neurosci., 22, 524, 10.1038/s41593-019-0352-0 · DOI · Paper page
  114. Shen, 2018, CRISPR-delivery particles targeting nuclear receptor-interacting protein 1 (Nrip1) in adipose cells to enhance energy expenditure, J. Biol. Chem., 293, 17291, 10.1074/jbc.RA118.004554 · DOI
  115. Lostale-Seijo, 2017, Peptide/Cas9 nanostructures for ribonucleoprotein cell membrane transport and gene edition, Chem. Sci., 8, 7923, 10.1039/C7SC03918B · DOI
  116. Qiao, 2019, Cytosolic delivery of CRISPR/Cas9 ribonucleoproteins for genome editing using chitosan-coated red fluorescent protein, Chem. Commun., 55, 4707, 10.1039/C9CC00010K · DOI
  117. Zhu, 2019, DNAzyme activated protein-scaffolded CRISPR-Cas9 nanoassembly for genome editing, Chem. Commun., 55, 6511, 10.1039/C9CC03172C · DOI
  118. Yang, 2019, Nanoscale ATP-responsive zeolitic imidazole framework-90 as a general platform for cytosolic protein delivery and genome Editing, J. Am. Chem. Soc., 141, 3782, 10.1021/jacs.8b11996 · DOI · Paper page
  119. Liu, 2019, A boronic acid-rich dendrimer with robust and unprecedented efficiency for cytosolic protein delivery and CRISPR-Cas9 gene editing, Sci. Adv., 5, 10.1126/sciadv.aaw8922 · DOI · Paper page
  120. Campbell, 2019, Gesicle-mediated delivery of CRISPR/Cas9 ribonucleoprotein complex for inactivating the HIV provirus, Mol. Ther., 27, 151, 10.1016/j.ymthe.2018.10.002 · DOI
  121. Wang, 2018, ARMMs as a versatile platform for intracellular delivery of macromolecules, Nat. Commun., 9, 960, 10.1038/s41467-018-03390-x · DOI · Paper page
  122. Chen, 2019, Friend or foe? evidence indicates endogenous exosomes can deliver functional gRNA and Cas9 protein, Small, 15, 10.1002/smll.201970205 · DOI
  123. Pan, 2019, Near-infrared upconversion-activated CRISPR-Cas9 system: a remote-controlled gene editing platform, Sci. Adv., 5, 10.1126/sciadv.aav7199 · DOI · Paper page
  124. Zhou, 2018, Enhanced cytosolic delivery and release of CRISPR/Cas9 by black phosphorus nanosheets for genome editing, Angew. Chem. Int. Ed., 57, 10268, 10.1002/anie.201806941 · DOI · Paper page
  125. Mircetic, 2017, Purified Cas9 fusion proteins for advanced genome manipulation, Small Methods, 1, 1600052, 10.1002/smtd.201600052 · DOI
  126. Wang, 2017, Genome editing for cancer therapy: delivery of Cas9 protein/sgRNA plasmid via a gold nanocluster/lipid core-shell nanocarrier, Adv. Sci., 4, 1700175, 10.1002/advs.201700175 · DOI · Paper page
  127. Ha, 2017, Poly-sgRNA/siRNA ribonucleoprotein nanoparticles for targeted gene disruption, J. Control. Release, 250, 27, 10.1016/j.jconrel.2017.02.007 · DOI
  128. Zhu, 2019, Spatial control of in vivo CRISPR-Cas9 genome editing via nanomagnets, Nat. Biomed. Eng., 3, 126, 10.1038/s41551-018-0318-7 · DOI
  129. Cox, 2015, Therapeutic genome editing: prospects and challenges, Nat. Med., 21, 121, 10.1038/nm.3793 · DOI · Paper page
  130. Liu, 1996, Homozygous defect in HIV-1 coreceptor accounts for resistance of some multiply-exposed individuals to HIV-1 infection, Cell, 86, 367, 10.1016/S0092-8674(00)80110-5 · DOI · Paper page
  131. Bachtarzi, 2017, Ex vivo and in vivo genome editing: a regulatory scientific framework from early development to clinical implementation, Regen. Med., 12, 8, 10.2217/rme-2017-0095 · DOI
  132. Ormond, 2019, The clinical application of gene editing: ethical and social issues, Pers. Med., 16, 337, 10.2217/pme-2018-0155 · DOI
  133. Cho, 2014, Analysis of off-target effects of CRISPR/Cas-derived RNA-guided endonucleases and nickases, Genome Res., 24, 132, 10.1101/gr.162339.113 · DOI · Paper page
  134. Bessis, 2004, Immune responses to gene therapy vectors: influence on vector function and effector mechanisms, Gene Ther., 11, S10, 10.1038/sj.gt.3302364 · DOI · Paper page
  135. Qi, 2018, Recent research and development of PLGA/PLA microspheres/nanoparticles: a review in scientific and industrial aspects, Front. Chem. Sci. Eng., 13, 14, 10.1007/s11705-018-1729-4 · DOI
  136. Baliou, 2018, CRISPR therapeutic tools for complex genetic disorders and cancer, Int. J. Oncol., 53, 443
  137. Baylis, 2017, First-in-human Phase 1 CRISPR gene editing cancer trials: are we ready?, Curr. Gene Ther., 17, 309
  138. Tang, 2016, Immune cell screening of a nanoparticle library improves atherosclerosis therapy, Proc. Natl. Acad. Sci. U. S. A., 113, E6731, 10.1073/pnas.1609629113 · DOI
  139. Jouannet, 2017, CRISPR-Cas9, germinal cells and human embryo, Biol. Aujourd'hui, 211, 207, 10.1051/jbio/2017032 · DOI
  140. Dever, 2017, The changing landscape of gene editing in hematopoietic stem cells: a step towards Cas9 clinical translation, Curr. Opin. Hematol., 24, 481, 10.1097/MOH.0000000000000385 · DOI · Paper page

Cited by

See all 184

Metadata

Authors
Xu, C.-F., Chen, G.-J., Luo, Y.-L., Zhang, Y., Zhao, G., Lu, Z.-D., Czarna, A., Gu, Z., & Wang, J.
Venue
Advanced Drug Delivery Reviews
Publisher
Elsevier BV
Published
2021-01
Volume
168
Pages
3-29
ISSN
0169-409X (ISSN-L)
OpenAlex
W2991378064
Cited by
184
References
63
FWCI
1.65
Type
journal article
Language
en
Open access
closed
Licence
  • www.elsevier.com/tdm/userlicense/1.0/ (tdm)
  • www.elsevier.com/legal/tdmrep-license (tdm)
Funders
  • UCLA
  • National Key R&D Program of China (2017YFA0205600)
  • National Natural Science Foundation of China (81801825, 81901875, 81971723, 51633008)
  • Program for Guangdong Introducing Innovative and Entrepreneurial Teams (2017ZT07S054)
  • Guangdong Provincial Pearl River Talents Program (2017GC010713)
  • Outstanding Scholar Program of Guangzhou Regenerative Medicine and Health Guangdong Laboratory (2018GZR110102001)
  • Fundamental Research Funds for the Central Universities

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.